The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characteristics and outcomes for patients (pts) with metastatic small cell urothelial carcinoma (mSCUC).
 
Nathaniel R. Wilson
No Relationships to Disclose
 
Jaanki Khandelwal
No Relationships to Disclose
 
Lianchun Xiao
No Relationships to Disclose
 
Amishi Yogesh Shah
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Exelixis; Pfizer/EMD Serono
Research Funding - 4D Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst)
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; crispr therapeutics; Infinity Pharmaceuticals; Janssen; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca
 
Sangeeta Goswami
No Relationships to Disclose
 
Craig A. Kovitz
Honoraria - Dendreon
Consulting or Advisory Role - Dendreon
 
Charles Guo
No Relationships to Disclose
 
Bogdan Czerniak
No Relationships to Disclose
 
Christopher Logothetis
Honoraria - Amgen; Bayer
Consulting or Advisory Role - Amgen; Bayer; Exelixis; Merck Sharp & Dohme
Research Funding - Aragon Pharmaceuticals (Inst); Janssen; Novartis; ORIC Pharmaceuticals (Inst)
 
Paul Gettys Corn
Research Funding - Janssen Oncology (Inst)
 
Nizar M. Tannir
Stock and Other Ownership Interests - Amgen; Arcturus Therapeutics; Arcus Biosciences; BioCryst; Corvus Pharmaceuticals; First Trust Amex Biotech (FBT); Johnson & Johnson/Janssen; Merck; Nuvation Bio; Revolution Medicines; Surface Oncology; Vanguard Health Care; Xencor
Honoraria - AstraZeneca/Merck; Bristol-Myers Squibb; Eisai; Exelixis; Intellisphere; Merck Sharp & Dohme; Neoleukin Therapeutics; Oncorena
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Merck Sharp & Dohme; Nektar; Oncorena
Research Funding - Arrowhead Pharmaceuticals (Inst); Bristol Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Nektar (Inst); Novartis (Inst)
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Basilea; Bavarian Nordic; Bristol-Myers Squibb; Curio Science; EMD Serono; Genentech; IDEAYA Biosciences; Immunomedics; Janssen; Loxo; Merck; Mirati Therapeutics; NCCN; Nektar; Seagen; Taiho Pharmaceutical
Research Funding - Basilea; BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Omar Alhalabi
Consulting or Advisory Role - Seagen